GNC Japan

What GNC Japan does

GNC Japan, formally GN Corporation Co., Ltd. (有限会社ジーエヌコーポレーション), is a privately held Japanese medical technology company headquartered in Kofu, Yamanashi, founded in 2005 and led by Representative Director and R&D Director Dr. Abraham Samuel. The company specializes in cell therapy, regenerative medicine, and bio-inert medical device solutions, with a portfolio that includes the BEES-HAUS and BHES-HAUS hybrid cell therapies for male urethral stricture, AIET cancer immunotherapy using autologous NK and T cells, the Eye-for-Eyes nano-composite corneal endothelial transplantation program, BLIS-COAT bio-inert coatings and STAR-MING bio-inert implants, and a beta-glucan supplement line (Nichi Glucan, Nichi BRITE, neu REFIX) currently suspended for technical improvements. Core scientific assets include Japanese and Indian patents, FDA Orphan Drug and Rare Pediatric Disease Designations for a Duchenne Muscular Dystrophy adjuvant, and a peer-reviewed publication record through JSRM and journals such as Nature Scientific Reports and Frontiers in Immunology.

The company's business model combines professional services and licensing: it monetizes through technology transfer and consulting engagements, market entry support for Japanese medical device companies entering India (via wholly-owned subsidiary Medinippon Healthcare in Chennai, established 2013), licensing of proprietary technologies to hospitals and partners such as Vinmec Hospital (Vietnam) and Apollo Hospitals (India), and previously through direct e-commerce of beta-glucan supplements. The go-to-market is event-driven and partnership-led, relying on academic conferences (NCRM NICHE since 2006), technology transfer MoUs, and a cross-border Japan-India research network spanning hospitals, universities and government bodies across Asia, Africa, Europe and the US.

GNC serves a mix of enterprise and institutional customers — tertiary hospitals seeking advanced cell therapies, pharmaceutical and biotech companies pursuing orphan drug pathways, Japanese medical device manufacturers entering India, and (historically) health-conscious consumers via the Nichiglucan online shop. Distribution channels include direct technology transfer to hospitals, channel/regulatory support via Medinippon Healthcare, the Nichiglucan e-commerce storefront (currently suspended), academic and research partnerships, and emerging technology integrations such as the HAUS SCORE AI tool co-developed with PageLightPrime.

Name

GNC Japan

Legal name

有限会社はuginCorporation

Website

https://gncorporation.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

GNC Japan (GN Corporation) is a privately held Japanese medical technology company that develops cell therapies, regenerative medicine solutions, and bio-inert medical devices, monetizing through technology licensing, consulting, and market entry support for healthcare institutions and device manufacturers across Asia, Africa, and beyond.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Technology Transfer & Consulting

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Investigator & Site Training / GCP Support (HLAGACAF)

akta.pro secondary industries

Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG), GxP Audits & Supplier Qualification (GMP/GCP/GLP/GDP) (HLAGAKAE)

Keywords

• Cell therapy technology
• Regenerative medicine solutions
• Medical technology transfer
• Beta-glucan supplements
• Medical device consulting

Headquarters

HQ city

Kofu

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Consulting and Research Services: Technology transfer and consulting services for cell therapy, medical devices, and regulatory support including FDA orphan drug designation assistance.
2. Technology Licensing: Licensing out proprietary technologies and patents (BEES-HAUS, corneal transplantation, drug adjuvants) to healthcare institutions and pharmaceutical companies.
3. Health Supplements (Nichi Glucan, Nichi BRITE, neu REFIX): Sale of functional food supplements containing beta-glucan. Products temporarily suspended due to technical improvements.
4. Market Entry Support Services: Supporting Japanese medical device manufacturers' entry into Indian market through Medinippon Healthcare subsidiary, including regulatory approval and distribution.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

GN Corporation (GNC Japan) is a Japan-based translational research and technology transfer company that develops and licenses proprietary cell therapies (BEES-HAUS, BHES-HAUS, AIET), bio-inert medical device technologies (BLIS-COAT, STAR-MING), and beta-glucan health supplements for global markets. The company also provides consulting, market entry support, and regulatory services through its Indian subsidiary Medinippon Healthcare, enabling Japanese medical innovations to reach hospitals and patients worldwide.

Product overview

GNC Japan operates as a translational research and technology transfer company specializing in regenerative medicine, cell therapies, and health supplements. The product portfolio centers on four core therapeutic areas: (1) Cell therapies including BEES-HAUS and BHES-HAUS for urethral stricture, AIET for cancer immunotherapy, and Eye-for-Eyes-Mission for corneal transplantation; (2) Medical devices including BLIS-COAT coatings and STAR-MING implants; (3) The Nichi Glucan brand of beta-glucan supplements encompassing nichi Glucan, nichi BRITE, and neu REFIX for immune enhancement, oncology nutrition, and rare diseases like Duchenne Muscular Dystrophy; and (4) Academic services through JSRM journal and NCRM NICHE conference. AI technology (HAUS SCORE) supports urethral stricture prediction.

Differentiator

Problem solved

Functional benefit

Brands

• Nichi Glucan: Beta-glucan food supplement containing AFO-202 strain of Aureobasidium Pullulans, marketed for immune enhancement
• Nichi BRITE
• neu REFIX
• BEES-HAUS
• BHES-HAUS
• AIET
• BLIS-COAT
• STAR-MING
• NCRM NICHE
• Edogawa NICHE Prize

Products and services

• BEES-HAUS (Buccal Epithelium Encapsulated Scaffold) A hybrid cell therapy using the patient's own buccal mucosal cells encapsulated in a polymer scaffold for the treatment of male urethral stricture, marketed to urology departments of hospitals via technology transfer and licensing.
• BHES-HAUS Simplified Cell Therapy Simplified version of the BEES-HAUS hybrid cell therapy protocol for male urethral stricture, designed for easier clinical adoption by urology centers.
• AIET (Autologous Immune Enhancement Therapy) Cancer immunotherapy using autologous peripheral blood-derived NK cells and T cells to enhance autoimmunity against cancer cells, transferred to overseas hospitals as a turnkey service including equipment, training, and medical material supply.
• Eye-for-Eyes-Mission Corneal Endothelial Cell Transplantation Corneal endothelial cell transplantation using nano-composite gel sheet technology that allows a single donor cornea to serve multiple patients, addressing global corneal donor shortages for hospitals and ophthalmology centers.
• BLIS-COAT Bio-Inert Coating Bio-inert coating technology applied to medical devices to improve biocompatibility, offered to medical device manufacturers via technology licensing and partnership.
• STAR-MING Bio-Inert Implant Bio-inert implant technology developed initially for facial cosmetic reconstruction and expanded into orthopedic applications, marketed to medical device companies and hospitals.
• nichi Glucan Beta-glucan food supplement containing AFO-202 strain of Aureobasidium Pullulans, marketed to health-conscious consumers in Japan for immune system enhancement and inflammatory cytokine regulation. Sales temporarily suspended for technical improvements.
• nichi BRITE Beta-glucan product (AFO-202 strain) targeted at overseas markets with researched clinical applications in oncology nutrition, Parkinson's disease, and pancreatic cancer, sold as a functional food supplement.
• neu REFIX Beta-glucan product containing N-163 strain of Aureobasidium Pullulans marketed for Duchenne Muscular Dystrophy support, Multiple Sclerosis, psoriasis, and gut microbiome health, sold as a functional food supplement.
• HAUS SCORE AI Tool AI-based scoring tool that analyzes male urethral stricture biomarkers and clinical data to predict recurrence, developed in partnership with PageLightPrime for use by urology clinicians.
• Cliny PEG Gastrostomy Kits (India distribution) Percutaneous endoscopic gastrostomy kits for enteral nutrition support, particularly for cancer patients unable to take oral intake, distributed in India by Medinippon Healthcare on behalf of Create Medic.
• Medical Technology Consulting & Market Entry Services Consulting services including market research in India and Mauritius, FDA and regulatory designation support (e.g., Orphan Drug and Rare Pediatric Disease Designation processes), and full technology transfer support for cell therapy and medical device manufacturers expanding internationally.
• JSRM (Journal of Stem Cells and Regenerative Medicine) Official peer-reviewed open access journal of the German Stem Cell Research Society, published since 2006, covering stem cell and regenerative medicine research including biomaterials and nanotechnology.
• NCRM NICHE Annual Conference Annual interdisciplinary academic conference in regenerative medicine held every October since 2006, gathering physicians, scientists, and industry experts for plenary sessions and young researcher competitions.

Quantifiable outcome

• Successfully transferred AIET cell therapy to Vinmec Hospital Vietnam (since 2018), extending survival and quality of life for cancer patients
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature9 records

Partnerships

17 partnerships are on record, tiered core, flagship and minor.

• Create Medic Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 April 2026Japanese medical device manufacturer supported by Medinippon Healthcare for Indian market entry. Products include Cliny PEG Gastrostomy kits and interventional radiology products. Create Medic India subsidiary established April 2026 in Chennai.
• PageLightPrimeflagshipTechnology or Integration · 1 March 2026AI solutions company based in Singapore and India partnering with GNC to develop HAUS SCORE AI tool for male urethral stricture markers. MoU signed March 2026 to create AI tool analyzing biomarkers and predicting recurrence. PageLightPrime USA to join for global database development.
• KMMC Kanyakumari Medical Mission Research Centre (India)minorStrategic or Co-development Partner · 1 August 2025Indian research center partnering for corneal regeneration translational research. Part of DMI Foundation network establishing Center of Excellence for regenerative medicine.
• St. Joseph University (Tanzania)minorStrategic or Co-development Partner · 1 August 2025Tanzanian university participating in corneal regeneration research collaboration for African market development.
• Be Well Hospital (India)minorStrategic or Co-development Partner · 1 August 2025Indian hospital participating in immune aging research (NLR studies) and clinical trials for beta glucan products.
• Right and Right Ventures (UK)minorStrategic or Co-development Partner · 1 August 2025UK-based company participating in corneal regeneration research collaboration.
• DMI St. Eugenie University (Zambia)minorStrategic or Co-development Partner · 1 August 2025Zambian university participating in African regenerative medicine research network.
• DMI St. John the Baptist University (Malawi)minorStrategic or Co-development Partner · 1 August 2025Malawian university participating in African regenerative medicine research network.
• Seoul Synergy (Mauritius)minorStrategic or Co-development Partner · 1 January 2022Mauritius-based research partner collaborating on immune biomarker studies, particularly NLR (neutrophil-lymphocyte ratio) research in HIV-positive populations.
• Okayama University (Japan)minorStrategic or Co-development Partner · 1 January 2020Joint research collaboration on cell culture and biomaterials tissue engineering utility. Research initiated December 2020.
• Hokkaido University (Japan)minorStrategic or Co-development Partner · 1 January 2020Collaboration to evaluate beta-glucan effects (Nyanwanglucan brand) in dogs for immunity benefits.
• Vinmec Hospital (Vietnam)coreStrategic or Co-development Partner · 1 January 2018Vietnamese hospital receiving AIET cell therapy technology transfer from GNC Corporation and NCRM since 2018. Serving as medical tourism hub for cancer treatment, achieving extended survival and improved quality of life for colorectal, lung, and liver cancer patients.
• Apollo Hospitals (India)coreStrategic or Co-development Partner · 1 January 2014NCRM technology partnership with Apollo Hospitals for blood cancer treatment using cell culture technology. In 2014, successfully performed India's first cell culture for blood cancer treatment using AIET combined with chemotherapy.
• Medinippon Healthcare (Indian Subsidiary)coreStrategic or Co-development Partner · 1 January 2013Indian subsidiary of GNC Corporation established in Chennai in 2013 to support Japanese medical technology and device market entry into India. Provides market research, CDSCO regulatory approval support, and distribution network development. Currently supporting Create Medic's Indian operations and developing scaffold products for global export from India.
• NCRM - Nichi-in Center for Regenerative MedicinecoreStrategic or Co-development Partner · 1 January 2005Japan-India joint research center for regenerative medicine. Co-founded by GNC Corporation with operations in Chennai (India) and Mauritius. NCRM has been operational since 2005 and serves as the primary research collaboration platform, issuing the JSRM academic journal and hosting the annual NCRM NICHE conference. GNC transfers Japanese technologies through NCRM to Indian and global markets.
• Global NICHE CorpminorStrategic or Co-development PartnerSister company for global expansion of Japanese technologies. Operating globally to extend GNC's reach beyond Japanese domestic market.
• Mauritius National AIDS SecretariatminorStrategic or Co-development PartnerGovernment body collaborating on HIV-positive population immune biomarker research.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Mesoblast Limited: Australian-listed global leader in cellular medicines with FDA-approved product (Remestemcel-L) for pediatric SR-aGvHD and pipeline in inflammatory diseases. Comparable to GNC's cell therapy development model with similar focus on immunomodulatory cell therapies, though at much larger commercial scale.
• Vericel Corporation: US commercial-stage cell therapy company with FDA-approved products (MACI for cartilage repair, Epicel for burns) generating over $200M in annual revenue. Comparable to GNC as a cell therapy company pursuing autologous cell-based regenerative medicine products in orthopedic and surgical indications.
• Reliance Life Sciences: India-based diversified biopharmaceutical company with established regenerative medicine business including stem cell therapies and bio-inert products. Comparable to GNC's India presence through Medinippon Healthcare and similar focus on bringing advanced therapies to the Indian market.

Direct peers

• JCR Pharmaceuticals Co., Ltd. Japan-based biopharmaceutical company with established cell therapy, regenerative medicine, and rare disease franchises including FDA-approved products. Comparable to GNC in Japanese HQ location, focus on rare diseases (including muscular dystrophy), and cell therapy platform approach.
• Healios K.K. Japanese cell therapy company developing stem cell treatments (MultiStem) for stroke, ARDS, and inflammatory diseases. Directly comparable as a Japan-listed cell therapy company advancing autologous cell therapies through technology transfer and clinical partnerships.
• Cellusion Inc. Japanese regenerative medicine company developing corneal endothelial cell therapy from iPS cells—directly comparable to GNC's Eye-for-Eyes-Mission nano-sheet technology. Both target the same donor cornea shortage problem with cell-based regenerative approaches and both operate in the Japanese cell therapy ecosystem.

Emerging players

• Cynata Therapeutics Limited: Australian clinical-stage stem cell company developing Cymerus MSC platform technology for multiple indications including graft-versus-host disease. Comparable to GNC as a platform cell therapy company pursuing multiple disease indications through technology licensing and partnerships.
• Pluristem Therapeutics Inc. Israeli clinical-stage cell therapy company developing placenta-derived mesenchymal-like cells for multiple indications including muscle regeneration and inflammatory diseases. Comparable to GNC's BEES-HAUS autologous cell therapy approach and similar focus on regenerative medicine partnerships.

Regional players

• Regrow Biosciences Pvt. Ltd. India-based cell therapy company specializing in autologous chondrocyte implantation and cartilage regeneration. Comparable to GNC's India-focused subsidiary operations and similar translational cell therapy business model in the Indian healthcare market.
• Stempeutics Research Pvt. Ltd. India-based stem cell therapy company developing mesenchymal stem cell products for osteoarthritis, critical limb ischemia, and liver cirrhosis. Comparable to GNC as India-headquartered regenerative medicine company with similar technology transfer and licensing model in the Indian market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/JapanGnc
• Facebookfacebook.com/profile.php?id=61588844175311
• LinkedInlinkedin.com/in/gn-corporation-co-ltd-894a821b4/?locale=en
• Instagraminstagram.com/ncrmniche

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GNC Japan